Physician-directed pharmaceutical advertising is regulated in the United States by the Food and Drug Administration (FDA); adherence to current FDA guidelines is unknown. Our objective was to determine adherence rates of physician-directed print advertisements in biomedical journals to FDA guidelines and describe content important for safe prescribing.
Methods and Findings
Cross-sectional analysis of November 2008 pharmaceutical advertisements within top U.S.-based biomedical journals publishing original research. We excluded advertisements for devices, over the counter medications, and disease awareness. We utilized FDA guideline items identifying unique forms of advertisement bias to categorize advertisements as adherent to FDA guidelines, possibly non-adherent to at least 1 item, or non-adherent to at least 1 item. We also evaluated advertisement content important for safe prescribing, including benefit quantification, risk information and verifiable references. All advertisements were evaluated by 2 or more investigators, with differences resolved by discussion. Twelve journals met inclusion criteria. Nine contained pharmaceutical advertisements, including 192 advertisements for 82 unique products; median 2 per product (range 1–14). Six “teaser” advertisements presented only drug names, leaving 83 full unique advertisements. Fifteen advertisements (18.1%) adhered to all FDA guidelines, 41 (49.4%) were non-adherent with at least one form of FDA-described bias, and 27 (32.5%) were possibly non-adherent due to incomplete information. Content important for safe prescribing was often incomplete; 57.8% of advertisements did not quantify serious risks, 48.2% lacked verifiable references and 28.9% failed to present adequate efficacy quantification. Study limitations included its focus on advertisements from a single month, the subjectivity of FDA guidelines themselves, and the necessary subjectivity of determinations of adherence.
Few physician-directed print pharmaceutical advertisements adhere to all FDA guidelines; over half fail to quantify serious risks. The FDA could better protect public health by creating new more objective advertisement guidelines requiring transparent presentation of basic safety and efficacy information.
Citation: Korenstein D, Keyhani S, Mendelson A, Ross JS (2011) Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing. PLoS ONE 6(8): e23336. https://doi.org/10.1371/journal.pone.0023336
Editor: Ulrich Thiem, Marienhospital Herne - University of Bochum, Germany
Received: March 30, 2011; Accepted: July 14, 2011; Published: August 17, 2011
Copyright: © 2011 Korenstein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Advertising is a crucial component of pharmaceutical industry marketing around the world and advertising in biomedical journals is estimated by industry to be its most profitable marketing strategy . Furthermore, physician exposure to advertisements has been associated with increased prescribing of advertised drugs . Beyond marketing, proponents of physician-directed advertisements, mostly from within the pharmaceutical industry, emphasize the important role advertisements play in educating physicians and other prescribers about new drugs . However, critics have raised concerns about the quality of the information presented in these physician-directed advertisements, including a focus on relative, not absolute, benefit – and poor referencing –. Although systematic assessments of advertisement content to promote evidence-based prescribing have been limited , , one previous study found that physician-directed advertisements did not promote guideline-adherent patient care , and critics have argued that advertising may harm patients and adversely impact public health .
In the United States, the Food and Drug Administration (FDA) is charged with regulating all pharmaceutical marketing through its Division of Drug Marketing and Advertising (DDMAC). However, ensuring advertisement adherence is challenging and FDA resources dedicated to this task are limited. DDMAC's fiscal year 2008 budget of $9 million  is dwarfed by the pharmaceutical industry's $58 billion marketing budget . While the FDA can require that companies change or remove non-adherent advertisements, given DDMAC's size and the volume of marketing materials it regulates, it would be unreasonable to expect each individual pharmaceutical advertisement to be reviewed.
Acknowledging this regulatory challenge, the FDA has recently asked physicians to report non-adherent or misleading advertisements through its “Bad Ad” program, explaining that “With your valuable assistance, FDA can be more effective in limiting the number of misleading promotional messages directed to health care professionals” . This program may prove useful in identifying grossly misleading advertisements; however there has been no systematic assessment of the adherence of physician-directed advertisements to FDA regulations in the last 20 years  and none to current standards, which were last updated in 2001.
Therefore, our objectives were to determine adherence to the 2001 FDA guidelines among current print advertisements directed at physicians within biomedical journals and to describe content important for safe prescribing. We performed a cross-sectional analysis of advertisements for prescription pharmaceuticals in top biomedical journals published in issues over a single month and hypothesized that rates of non-adherence to FDA guidelines would be high and that many advertisements would not present complete information important for safe prescribing.
We conducted a cross-sectional analysis of advertisements for prescription pharmaceuticals in top U.S. biomedical journals. We included all U.S.-based journals with a Thomson Institute for Scientific Information impact factor >10 that published original research. We excluded journals publishing only review articles and journals without a print edition.
We identified all advertisements for prescription pharmaceuticals published in any issue during November 2008. We excluded advertisements for devices and over-the counter medications and those designed to heighten awareness of particular diseases without mention of disease pharmacotherapy. Multiple different advertisements for the same product were all included but duplicate advertisements for the same prescription pharmaceutical were included only once in our sample.
Our advertisement assessment tool contained 36 items, of which 3 described basic characteristics of the advertised drug (e.g. is the drug a combination pill?), 4 described basic features of the advertisement (e.g. are there efficacy claims?), 21 were adapted from FDA guidelines , described below, and 8 related to advertisement content in support of safe prescribing, described below (see data collection tool in Figure S1).
Advertisement Assessment: FDA Guidelines
Our advertisement assessment tool included items based on FDA Prescription Drug Advertising Guidelines. 16FDA guidelines describe 21 unique items used to classify advertisements as “false, lacking in fair balance, or otherwise misleading” . We classified the items covered by these FDA guidelines into four non-exclusive content domains: drug safety (4 items), drug efficacy (10 items), references (7 items), and other items, which included quotes (3 items), statistics (2 items), headlines (1 item), and photographs (1 item).
Advertisement Assessment: Safe Prescribing and Other Content
Our assessment tool also included descriptive items and items related to content important for safe prescribing. Safe prescribing content items were based on prior literature , , ,  and accepted standards for the clinical application of data . These items focused on the presence of verifiable references and the quantification of risks and benefits with inclusion of appropriate efficacy numbers, defined as information adequate to calculate number needed to treat , or survival times in the case of chemotherapeutic agents. To further clarify the presentation of risks and benefits, we recorded the presence of a black box warning for each advertised drug and whether the drug places patients at risk for death or serious morbidity. In addition, we categorized advertised drugs into four product types based on indications for their use in the treatment of conditions related to cardiovascular/diabetes, psychiatric, hematology/oncology or other diseases.
Advertisement Review and Evaluation
Prior to initiating our reviews, we examined advertisements which had received FDA warning letters in 2008 (of which none was in our sample) to determine the approach of FDA to the regulations. All advertisements were reviewed between January and December of 2009. Each advertisement was reviewed by at least 2 of 3 investigators (DK, SK and JSR) and we attempted to determine adherence in a way that was slightly more conservative than the approach of the FDA itself (i.e. less likely to rate advertisements as non-adherent). During advertisement review, we referred directly to the FDA language embedded within our assessment tool (see data collection tool in the Figure S1) and utilized objective measures when possible. We discussed each item until consensus was reached and were intentionally conservative when rating the presence of FDA-described features, erring toward classifying advertisements as guideline adherent. Table S1 describes our approach to FDA item scoring.
Options for abstraction item responses included “yes” and “no”, with additional options of “not applicable” and “not sure” where appropriate. We coded the majority of items based only on the content of the advertisement as presented in the journal, but for items related to drug status as a first-line agent we used the 2008 Tarascon Pocket Pharmacopoeia® (Jones and Bartlett; Sudbury, MA) and for items related to the completeness of references and drug-associated risk of death or serious morbidity we searched Medline using the internet site pubmed.gov, considering only data published before October 2008. To establish black box warnings, we utilized the internet site blackboxrx.com, considering only warnings issued prior to October 2008.
Advertisements were categorized as adherent, non-adherent, or possibly non-adherent to FDA guidelines. Advertisements were considered adherent if they contained none of the 21 features used by FDA to classify advertisements as misleading, non-adherent if they contained one or more of the features used by FDA to classify advertisements as misleading, and possibly non-adherent if there were no features clearly defining a misleading ad but at least 1 of those items for which information was incomplete.
We used descriptive statistics to report rates of advertisement adherence, non-adherence, and possible non-adherence, overall and categorized by item content (i.e., safety, efficacy, references, other) and by pharmaceutical product indication (i.e., cardiovascular/diabetes, psychiatric, hematology/oncology or other). We then used Chi-square tests to test for differences in these advertisement non-adherence rates. Two reviewers (DK and JSR) independently reviewed a randomly selected 5% sub-sample of advertisements in order to measure inter-rater reliability and agreement beyond chance (kappa). Analyses were performed using JMP 7.1 (SAS Institute, Inc., Cary, NC). All statistical tests were 2-tailed and used a type I error rate of 0.05.
Twelve biomedical journals met our inclusion criteria. Three contained no advertisements for prescription pharmaceuticals (CA, Journal of the National Cancer Institute and Gastroenterology); 9 contained advertisements that were included in our study: Annals of Internal Medicine (n = 14 advertisements), Archives of General Psychiatry (n = 5), Blood (n = 36), Circulation (n = 9), Hepatology (n = 2), JAMA (n = 10), Journal of the American College of Cardiology (n = 25), Journal of Clinical Oncology (n = 56), and the New England Journal of Medicine (n = 35). We reviewed a total of 193 advertisements published during November 2008, of which one was a correction of a previous advertisement and was excluded from further analysis. Our final sample included 89 unique advertisements for 82 products. Seven products were represented in 2 unique advertisements each; the remaining 103 non-unique advertisements were duplicates, with a median of 2 advertisement appearances per product (range 1–14). Thirty-six manufacturers advertised products in our sample, with a median of 3 advertisements (range 1–21) and 2 unique advertisements (range 1–7) per company. Of the 89 unique advertisements, 6 (6.7%) were “teaser” advertisements, presenting only the drug name without additional content; the remaining 83 (93.3%) were full advertisements and were the focus of our analysis (Table 1).
Six of the 83 (7.2%) full unique advertisements were for “combination–pill” pharmaceutical products and 18 (21.7%) were for second line agents. More than half of advertised products (n = 43) had an indication for use for hematology/oncology-related treatment, 17 for cardiovascular/diabetes-related treatment, 7 for psychiatric-related treatment and 16 for other indications (Table 1). Our inter-rater reliability with regard to ratings of FDA guideline items was excellent, with 90.3% agreement and a kappa of 0.860.
Adherence to FDA guidelines
Among the 83 unique full advertisements, 15 (18.1%) were fully adherent to FDA guidelines, 41 (49.4%) were non-adherent to at least 1 FDA mandated item, and 27 (32.5%) were possibly non-adherent due to incomplete information (Table 2). Among the 41 advertisements that were non-adherent to at least 1 FDA item, the mean number of items to which the advertisement was non-adherent was 1.37 (SD = 0.73, range 1–4) and among the 68 advertisements that were non-adherent or possibly non-adherent, the mean number of items to which the advertisement was non-adherent or possibly non-adherent was 3.51 (SD = 2.62, range 1–11). Forty (48.2%) advertisements were categorized as possibly non-adherent due to an absence of verifiable references in support of efficacy or safety claims. The most common FDA criteria to which advertisements were non-adherent or possibly non-adherent are shown in Table 3, with descriptions of specific non-adherent advertisements.
There were statistically significant differences in non-adherence rates to FDA guidelines by item content. Nine (10.8%) advertisements were non-adherent to at least 1 FDA item focused on safety, whereas 18 (21.7%) advertisements were non-adherent to at least 1 FDA item focused on efficacy (p = 0.06)16 (19.3%) to at least 1 FDA item focused on references (p = 0.13), and 23 (27.7%) to at least 1 FDA item focused on other issues (p = 0.006) (Table 3). Among items focused on other issues, rates of non-adherence varied (Table 2).
There were statistically significant differences in non-adherence rates to FDA guidelines by product indication category. Four of 16 (25.0%) advertisements for “other use” pharmaceutical products were non-adherent to at least 1 FDA item, whereas 26 of 43 (60.5%) advertisements for hematology/oncology products were non-adherent to at least 1 FDA item (p = 0.01), 9 of 17 (52.9%) advertisements for cardiovascular/diabetes products were non-adherent to at least 1 FDA item (p = 0.10), and 2 of 7 (28.6%) advertisements for psychiatric products were non-adherent to at least 1 FDA item (p = 0.99).
Safe Prescribing Content
Many advertised drugs in our sample presented potential risks to patients, with 31 (37.3%) containing black box warnings and 33 (39.8%) placing patients at risk for death or serious morbidity. However, when evaluating advertisement content important for safe prescribing, we found that many physician-directed advertisements lacked important information. The majority (n = 48; 57.8%) did not quantify serious risks and 24 (28.9%) failed to present appropriate numbers to quantify benefits. Thirty-six advertisements (43.4%) referenced “data on file” and 40 (48.2%) lacked verifiable references, due either to an absence of any references or to the presence of references only to “data on file” or the product's package insert (Table 4).
In this study we found that nearly half of physician-directed advertisements fail to adhere to at least one FDA guideline regulating content. Physician-directed advertisements contained bias with regard to a wide variety of issues across content areas addressed by FDA guidance; there was no single problem that was consistently identified for non-adherence. In addition, we found that advertisements do a poor job of conveying basic information necessary for safe prescribing, with the majority failing to quantify serious risks, more than one quarter failing to quantify benefits and nearly half providing no verifiable references. Our study is the first in nearly 20 years to provide a systematic assessment of the adherence of U.S. advertisements to FDA guidance and provides context to inform the FDA's new “bad ad” program.
Despite the high rates of FDA non-adherence, the mean number of biased features in each advertisement was low and most advertisements we reviewed satisfied the majority of FDA-guidelines despite a general absence of content important for safe prescribing. FDA guidelines, though detailed, do not target many of the ad features most important for providing prescribers with useful information. For instance, FDA emphasizes avoiding frankly false information and balancing efficacy and safety information  but does little to encourage the presentation of useful and accurate information. An advertisement containing no specific efficacy claim, no quantification of drug safety and no verifiable references would adhere fully to FDA guidelines, despite presenting no practical information for clinicians. We found many such advertisements in our sample; for example an advertisement for a new chemotherapeutic agent presented the indication, the claim that it was the first in a new drug class, a vague image, and safety information with no quantification of effect and no references.
The expectation that advertisements should inform rational prescribing by presenting complete drug safety and efficacy information may be unrealistic since advertisements primarily serve a marketing function  and are not designed to train physicians to properly prescribe. However, proponents of physician-directed advertising emphasize the important role advertisements play in educating physicians and other prescribers about new drugs , and it is clear that advertisements do serve to influence prescribing by providing information to physicians. While the majority of physicians deny that advertisements inform their prescribing , marketing research has consistently shown that journal advertising is the most profitable form of drug marketing, with an estimated return on investment of $5 for every dollar spent . Furthermore, in some cases exposure to physician-directed advertising has been shown to be associated with less effective, lower quality prescribing decisions . It is clear that prescribers are ultimately responsible for the safety and efficacy of drugs they prescribe but few doctors recognize the extent to which they are influenced . Physicians should ensure that their prescribing is informed by the clinical literature and not by marketing materials. However, given the high risk associated with many advertised drugs, any tendency of advertisements to encourage inappropriate prescribing may pose dangers to patients. If FDA is truly committed to improving prescribing and protecting the health of the public it should demand that content important for safe and effective prescribing be consistently presented in physician-directed advertisements.
A major challenge of our study was performing advertisement evaluations given the subjectivity of the current FDA guidelines. For instance, the FDA describes that advertisements are misleading if they use “a quote or paraphrase out of context to convey a false or misleading idea” or “headline, subheadline, or pictoral or other graphic matter in a way that is misleading”, without providing explicit definitions. We created objective criteria for many items but scoring still required subjective determinations. Our conservative approach to subjective items may have underestimated the true non-adherence rate of the advertisements we evaluated, which may explain why the rate of advertisement non-adherence in our study is lower than the 92% non-adherence rate demonstrated in a 1990 study of journal advertisements directed at physicians .
There are several other important limitations to our study. First, we sampled advertisements from a single month in 2008, so we cannot comment on trends in advertisement characteristics over time. We focused on high-impact biomedical journals publishing original research, excluding lower-impact and more narrowly focused publications and those publishing clinical reviews, which may also be frequently read among clinicians. We may have missed important differences in advertisements published in these other types of publications and we expect the volume of advertisements to have been greater in these journals. However, we suspect that major differences in advertising content are unlikely since pharmaceutical company advertisements are generally created for use in many journals, not just the highest-impact journals. We did not evaluate advertisements presented in other contexts (e.g. direct mailings to physicians) or other media (e.g. online). Data on the influence of newer marketing strategies is limited but journal advertisements appear to remain influential . In addition, while visual aspects of advertisements may be highly influential, a full content analysis of advertisement imagery was beyond the scope of this paper. We did note a few patient photos which were misleading enough to lead to FDA non-adherence, but it is likely that other advertisements utilized more subtle imagery to imply more efficacy or broader patient applicability; thus our analysis may underestimate the misleading nature of some advertisements. Further, the items we measured to evaluate information important for safe prescribing were not validated, although the importance of quantifying benefits and risks is generally accepted  and the concepts evaluating safe prescribing are straightforward.
Our findings have important policy implications. The FDA has demonstrated a desire to improve the quality of pharmaceutical advertisements, most recently by enlisting doctors to review advertisements through its “Bad Ad” program. FDA should now move to update and simplify its guidelines for physician advertisements to facilitate the review process. Updated FDA guidelines should be straightforward and objective, and should include requirements that physician advertisements present clear risk quantification, absolute benefit information, description of the appropriate population to receive the drug, and verifiable references, either to the peer-reviewed published literature or to studies registered within federally-sponsored internet sites such as ClinicalTrials.gov in the case of unpublished data. These new guidelines might be applicable only to physician-directed advertisements, with separate guidance for DTC material, with greater focus on safety issues. Enforcement would still be necessary, as in other nations advertisements have failed to adhere to new straightforward requirements . However, new objective requirements would serve to enhance prescribing and public health by improving the quality, accuracy and transparency of advertisements, simplify at least part of the FDA review process, and facilitate physician participation in reporting “bad” advertisements.
In conclusion, we found low rates of adherence to FDA guidelines among physician directed pharmaceutical advertisements and inadequate information for safe prescribing. Advertising is a form of free speech and is a constitutionally protected right of industry . However, in keeping with its mission to “protect the public health by helping to ensure that prescription drug information is truthful, balanced, and accurately communicated”  the FDA can ensure that the information provided in advertisements leads to safe and effective prescribing on the part of clinicians. Current FDA guidelines are subjective and challenging to enforce and do not emphasize transparency and the inclusion of basic information relevant to prescribing. Increased enforcement of the current regulations would help improve advertisements, but the subjectivity of the guidelines presents a substantial barrier. We are hopeful that an update in FDA regulations, with increased emphasis on the transparent presentation of basic safety and efficacy information, might improve the quality of information provided in physician-directed pharmaceutical advertisements.
FDA Guideline Item Content Domains and Approach to Determining Advertisement Adherence.
Conceived and designed the experiments: DK SK JSR. Performed the experiments: DK SK JSR. Analyzed the data: JSR. Contributed reagents/materials/analysis tools: DK SK AM JSR. Wrote the paper: DK SK AM JSR.
- 1. Neslin S (2001) RAPP Study Executive Summary. Available from: http://www.docstoc.com/docs/69287888/ROI-Analysis-of-Pharmaceutical-Promotion-(RAPP)-An-Independent.
- 2. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, et al. (2010) Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Medicine 7(10): e1000352.
- 3. Dubois R (2003) Pharmaceutical Promotion: Don't Throw The Baby Out With The Bathwater. Health Affairs (Millwood) W3: 96–103.
- 4. Lexchin J (1999) How patient outcomes are reported in drug advertisements- Review of Canadian medical journals. Canadian Family Physician 45: 1213–1216.
- 5. Othman N, Vitry A, Roughead EE (2009) Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. PLoS ONE 4(7): e6350.
- 6. Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A (2004) Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiology and Drug Safety 13: 789–795.
- 7. Mindell J, Kemp T (1997) Only two fifths of advertisements cited published, peer reviewed references. BMJ 315: 1622.
- 8. Smart S, Williams C (1997) Half of drug advertisements in BMJ over six months cited no supporting evidence. BMJ 315: 1622.
- 9. Spielmans GI, Thielges SA, Dent AL, Greenberg RP (2008) The Accuracy of Psychiatric Medication Advertisements in Medical Journals. The Journal of Nervous and Mental Disease 196: 267–273.
- 10. Villanueva P, Peiro S, Librero J (2003) Accuracy of pharmaceutical advertisements in medical journals. The Lancet 361: 27–32.
- 11. Montgomery BD, Mansfield PR, Spurling GK, Ward AM (2008) Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study. BMC Public Health 8: 167.
- 12. Brody H, Light DW (2011) The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. American Journal of Public Health 101: 399–404.
- 13. Thaul S (2009) Direct to Consumer Advertising of Prescription Drugs. Congressional Research Service, R40590. Available from: http://www.law.umaryland.edu/marshall/crsreports/crsdocuments/RL3285303252005.pdf.
- 14. Gagnon M-A, Lexchin J (2008) The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Medicine 5(1): e1.
- 15. Hamburg MADear Healthcare Professional Letter. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/DrugMarketingAdvertisingandCommunications/UCM211560.pdf.
- 16. Wilkes MS, Doblin BH, Shapiro MF (1992) Pharmaceutical Advertisements in Leading Medical Journals: Experts Assessments. Annals of Internal Medicine 116: 912–919.
- 17. Food and Drug Administration. Prescription Drug Advertising (2001) Available from: http://edocket.access.gpo.gov/cfr_2001/aprqtr/pdf/21cfr202.1.pdf.
- 18. McAlister FA, Straus SE, Guyatt GH, Haynes RB (2000) Users' Guides to the Medical Literature XX. Integrating Research Evidence With the Care of the Individual Patient. JAMA 283: 2829–2836.
- 19. Food and Drug Administration2009 Warning Letters and Untitled Letters to Pharmaceutical Companies. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm055773.htm.
- 20. Fugh-Berman A, Alladin K, Chow J (2006) Advertising in Medical Journals: Should Current Practice Change? PLoS Medicine 3(6): e130.
- 21. Spiller LD, Wymer WWJ (2001) Physicians' Perceptions and Uses of Commercial Drug Information Sources: An Examination of Pharmaceutical Marketing to Physicians. Health Marketing Quarterly 19: 91–106.
- 22. Norris P, Herxheimer A, Lexchin J, Mansfield P (2004) Drug Promotion - What We Know, What We Have Yet to Learn - Reviews of Materials in the WHO/HAI Database on Drug Promotion - EDM Research Series No. 032. Available from: http://apps.who.int/medicinedocs/en/d/Js8109e/2.html.
- 23. Korenstein D, Keyhani S, Ross J (2010) Physician attitudes toward industry: a view across the specialties. Archives of Surgery 145: 570–577.
- 24. McGettigan P, Golden J, Fryer J, Chan R, Feely J (2001) Prescribers prefer people: The sources of infomration used by doctors for prescribing suggests that the medium is more important than the message. British Journal of Clinical Pharmacology 51: 184–189.
- 25. Santiago MG, Bucher HC, Nordmann AJ (2008) Accuracy of drug advertisements in medical journals under new law regulating the marketing of pharmaceutical products in Switzerland. BMC Medical Informatics and Decision Making 8: 61.
- 26. Shuchman M (2007) Drug Risks and Free Speech- Can Congress Ban Consumer Drug Ads? New England Journal of Medicine 356: 2236–2239.
- 27. FDA Regulates Prescription Drug Promotion (2003) The Senate Special Committee on Aging, United States Department of Health and Human Services. Available from: http://www.hhs.gov/asl/testify/t030722b.html.